IBDEI12I ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,18844,1,4,0)
 ;;=4^733.00
 ;;^UTILITY(U,$J,358.3,18844,1,5,0)
 ;;=5^Osteoporosis NOS
 ;;^UTILITY(U,$J,358.3,18844,2)
 ;;=^87159
 ;;^UTILITY(U,$J,358.3,18845,0)
 ;;=278.00^^105^1223^40
 ;;^UTILITY(U,$J,358.3,18845,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18845,1,4,0)
 ;;=4^278.00
 ;;^UTILITY(U,$J,358.3,18845,1,5,0)
 ;;=5^Obesity
 ;;^UTILITY(U,$J,358.3,18845,2)
 ;;=^84823
 ;;^UTILITY(U,$J,358.3,18846,0)
 ;;=278.01^^105^1223^39
 ;;^UTILITY(U,$J,358.3,18846,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18846,1,4,0)
 ;;=4^278.01
 ;;^UTILITY(U,$J,358.3,18846,1,5,0)
 ;;=5^Morbid Obesity
 ;;^UTILITY(U,$J,358.3,18846,2)
 ;;=^84844
 ;;^UTILITY(U,$J,358.3,18847,0)
 ;;=250.80^^105^1223^10
 ;;^UTILITY(U,$J,358.3,18847,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18847,1,4,0)
 ;;=4^250.80
 ;;^UTILITY(U,$J,358.3,18847,1,5,0)
 ;;=5^DM Type II with LE Ulcer
 ;;^UTILITY(U,$J,358.3,18847,2)
 ;;=DM Type II with LE Ulcer^267846^707.10
 ;;^UTILITY(U,$J,358.3,18848,0)
 ;;=250.00^^105^1223^5
 ;;^UTILITY(U,$J,358.3,18848,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18848,1,4,0)
 ;;=4^250.00
 ;;^UTILITY(U,$J,358.3,18848,1,5,0)
 ;;=5^DM Type II Dm W/O Complications
 ;;^UTILITY(U,$J,358.3,18848,2)
 ;;=^33605
 ;;^UTILITY(U,$J,358.3,18849,0)
 ;;=250.40^^105^1223^6
 ;;^UTILITY(U,$J,358.3,18849,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18849,1,4,0)
 ;;=4^250.40
 ;;^UTILITY(U,$J,358.3,18849,1,5,0)
 ;;=5^DM Type II Dm with Nephropathy
 ;;^UTILITY(U,$J,358.3,18849,2)
 ;;=^267837^583.81
 ;;^UTILITY(U,$J,358.3,18850,0)
 ;;=250.50^^105^1223^9
 ;;^UTILITY(U,$J,358.3,18850,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18850,1,4,0)
 ;;=4^250.50
 ;;^UTILITY(U,$J,358.3,18850,1,5,0)
 ;;=5^DM Type II w/ PDR
 ;;^UTILITY(U,$J,358.3,18850,2)
 ;;=DM Type II w/ PDR^267839^362.02
 ;;^UTILITY(U,$J,358.3,18851,0)
 ;;=250.60^^105^1223^7
 ;;^UTILITY(U,$J,358.3,18851,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18851,1,4,0)
 ;;=4^250.60
 ;;^UTILITY(U,$J,358.3,18851,1,5,0)
 ;;=5^DM Type II Dm with Neuropathy
 ;;^UTILITY(U,$J,358.3,18851,2)
 ;;=^267841^357.2
 ;;^UTILITY(U,$J,358.3,18852,0)
 ;;=250.70^^105^1223^8
 ;;^UTILITY(U,$J,358.3,18852,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18852,1,4,0)
 ;;=4^250.70
 ;;^UTILITY(U,$J,358.3,18852,1,5,0)
 ;;=5^DM Type II Dm with Peripheral Vasc Dis
 ;;^UTILITY(U,$J,358.3,18852,2)
 ;;=^267843^443.81
 ;;^UTILITY(U,$J,358.3,18853,0)
 ;;=250.01^^105^1223^4
 ;;^UTILITY(U,$J,358.3,18853,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18853,1,4,0)
 ;;=4^250.01
 ;;^UTILITY(U,$J,358.3,18853,1,5,0)
 ;;=5^DM Type I DM W/O Complications
 ;;^UTILITY(U,$J,358.3,18853,2)
 ;;=^33586
 ;;^UTILITY(U,$J,358.3,18854,0)
 ;;=272.0^^105^1223^22
 ;;^UTILITY(U,$J,358.3,18854,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18854,1,4,0)
 ;;=4^272.0
 ;;^UTILITY(U,$J,358.3,18854,1,5,0)
 ;;=5^Hypercholesterolemia, Pure
 ;;^UTILITY(U,$J,358.3,18854,2)
 ;;=Hypercholesterolemia, Pure^59973
 ;;^UTILITY(U,$J,358.3,18855,0)
 ;;=272.1^^105^1223^28
 ;;^UTILITY(U,$J,358.3,18855,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18855,1,4,0)
 ;;=4^272.1
 ;;^UTILITY(U,$J,358.3,18855,1,5,0)
 ;;=5^Hypertriglyceridemia, Pure
 ;;^UTILITY(U,$J,358.3,18855,2)
 ;;=Hypertriglyceridemia, Pure^101303
 ;;^UTILITY(U,$J,358.3,18856,0)
 ;;=272.2^^105^1223^24
 ;;^UTILITY(U,$J,358.3,18856,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18856,1,4,0)
 ;;=4^272.2
 ;;^UTILITY(U,$J,358.3,18856,1,5,0)
 ;;=5^Hyperlipidemia, Mixed
 ;;^UTILITY(U,$J,358.3,18856,2)
 ;;=^78424
 ;;^UTILITY(U,$J,358.3,18857,0)
 ;;=275.42^^105^1223^21
 ;;^UTILITY(U,$J,358.3,18857,1,0)
 ;;=^358.31IA^5^2
 ;;
 ;;$END ROU IBDEI12I
